SP-102 (SEMDEXA™)

About SCILEX

Scilex Holding Company (Nasdaq: SCLX) is a revenue-generating biopharmaceutical company dedicated to becoming a global leader in non-opioid pain management. Its strategy combines the commercialization of acquired, approved products like ZTlido®, Elyxyb®, and Gloperba® with the development of a proprietary pipeline, including the late-stage injectable candidate SEMDEXA™ for sciatica. Founded in 2013 and headquartered in Palo Alto, California, Scilex is positioned at the critical intersection of drug delivery innovation and the urgent societal need to address the opioid crisis.

About Scilex Holding

Scilex Holding is a revenue-generating biopharma company singularly focused on building a leading franchise in non-opioid pain management. Its strategy combines the commercialization of three approved products—ZTlido®, Elyxyb®, and Gloperba®—with the development of a late-stage pipeline, headlined by SEMDEXA™ (SP-102) for sciatica, which has completed a successful Phase 3 trial. The company aims to address the opioid crisis by providing healthcare providers and patients with effective, non-addictive therapeutic options across a spectrum of pain indications, from neuropathic pain to migraine and gout prophylaxis.

Therapeutic Areas